Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.

Ou T, Wang W, Yong H, Hao H, Wang R, Dai X, Wang D, Li Y

Alternative therapies in health and medicine1 Sept 2022Cited by 2 (Europe PMC)

PMID35751892PepBankPUB-35751892

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, liraglutide plus dapagliflozin gave higher clinical efficacy than liraglutide alone after the intervention.
In plain wordsIn adults with diabetes and metabolic syndrome, liraglutide plus dapagliflozin worked better than liraglutide alone.
Peptide
Liraglutide
Outcome
IncreaseClinical efficacy
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Postintervention, the clinical efficacy was significantly higher in the intervention group than in the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189201
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, liraglutide plus dapagliflozin gave lower glycolipid metabolism levels than liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, sugar and fat blood levels were lower with liraglutide plus dapagliflozin than with liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseGlycolipid metabolism
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The intervention group had significantly lower glycolipid metabolism and inflammatory-factor levels than the control group UA and MAU had declined in both groups but were significantly lower in the intervention group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189202
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, liraglutide plus dapagliflozin gave lower inflammatory-factor levels than liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, inflammation markers were lower with liraglutide plus dapagliflozin than with liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseInflammatory factor levels
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The intervention group had significantly lower glycolipid metabolism and inflammatory-factor levels than the control group UA and MAU had declined in both groups but were significantly lower in the intervention group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, uric acid fell in both groups and was significantly lower with liraglutide plus dapagliflozin than with liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, uric acid fell in both groups, and fell more with liraglutide plus dapagliflozin.
Peptide
Liraglutide
Outcome
DecreaseUric acid
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
The intervention group had significantly lower glycolipid metabolism and inflammatory-factor levels than the control group UA and MAU had declined in both groups but were significantly lower in the intervention group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189204
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, microalbuminuria fell in both groups and was significantly lower with liraglutide plus dapagliflozin than with liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, urine albumin fell in both groups, and fell more with liraglutide plus dapagliflozin.
Peptide
Liraglutide
Outcome
DecreaseMicroalbuminuria
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
The intervention group had significantly lower glycolipid metabolism and inflammatory-factor levels than the control group UA and MAU had declined in both groups but were significantly lower in the intervention group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189205
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, LVEF rose in both groups, with a significantly greater rise with liraglutide plus dapagliflozin than with liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, heart pumping function rose in both groups, and rose more with liraglutide plus dapagliflozin.
Peptide
Liraglutide
Outcome
IncreaseLeft ventricular ejection fraction
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
The left ventricular ejection fraction (LVEF) increased and the left ventricular end diastolic diameter (LVEDd) decreased in both groups, but the intervention group had significantly greater changes as compared with those in the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189206
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, LVEDd fell in both groups, with a significantly greater fall with liraglutide plus dapagliflozin than with liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, heart chamber size fell in both groups, and fell more with liraglutide plus dapagliflozin.
Peptide
Liraglutide
Outcome
DecreaseLeft ventricular end diastolic diameter
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
The left ventricular ejection fraction (LVEF) increased and the left ventricular end diastolic diameter (LVEDd) decreased in both groups, but the intervention group had significantly greater changes as compared with those in the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189207
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with diabetes and metabolic syndrome, quality of life was better with liraglutide plus dapagliflozin than with liraglutide alone.
In plain wordsIn adults with diabetes and metabolic syndrome, quality of life was better with liraglutide plus dapagliflozin than with liraglutide alone.
Peptide
Liraglutide
Outcome
IncreaseQuality of life
Study
n = 125
Comparator
Liraglutide 0.6 mg alone
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
The intervention group was also superior to the control group in patients' QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group.
Summary · context
The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3575189208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.